Immunoglobulin replacement therapy, first administered in the 1980’s, has been the mainstay of treatment for primary and secondary immunodeficiencies. In the past, the most common treatment for immunoglobulin replacement was by intravenous infusion every 3-4 weeks. This is moving towards weekly subcutaneous immunoglobulin (SCIg) which can be self-administered by patients.
The Springfusor is the ideal device to deliver SCIg, with the advantages including:
- No alarms
- No batteries
- No rate setting required
- Low pump cost
- Lightweight and portable
Switching to self-administered SCIg has been shown to improve the quality of life and perceptions of general health in both adults and children, with improvements in pain and vitality and fewer days missed from school or work.